Evidence map›Paper›PMID 36575011›Full record

ReviewInternal medicine (Tokyo, Japan)2023

Relapsing Anti-MOG Antibody-associated Disease following COVID-19 Vaccination: A Rare Case Report and Review of the Literature.

Hiroto Nakano, Kazuyoshi Yamaguchi, Naoyuki Hama, Yasuko Matsumoto, Moeko Shinohara, Hisashi Ide

Open access · diamondAbstract readReviewCase Reports
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Movement Disorders in MOGAD: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hiroto NakanoDepartment of Neurology, Ishikawa Prefectural Central Hospital, Japan.
Kazuyoshi YamaguchiDepartment of Neurology, Ishikawa Prefectural Central Hospital, Japan.
Naoyuki HamaDepartment of Neurology, Ishikawa Prefectural Central Hospital, Japan.
Yasuko MatsumotoDepartment of Neurology, Ishikawa Prefectural Central Hospital, Japan.
Moeko ShinoharaDepartment of Neurology, Kaga Medical Center, Japan.
Hisashi IdeDepartment of Neurosurgery, Kaga Medical Center, Japan.
Ishikawa Prefectural Central Hospital · JPShiga Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune demyelinating disorder that mainly occurs post-infection or post-vaccination. MOGAD after inoculation with coronavirus disease 2019 (COVID-19) vaccines is rare, and we herein report a rare case of a patient with MOGAD after vaccination using the Pfizer-BioNTech COVID-19 vaccine (BNT162b2, Pfizer Japan, Tokyo). Our report highlights the fact that MOGAD following inoculation with COVID-19 vaccine may show clinical relapse during reduction of the oral steroid dose, and continuous treatments with immunological agents is needed to prevent disease recurrence.

Indexed as

Autoimmune DiseasesCOVID-19AutoantibodiesBNT162 VaccineCOVID-19 VaccinesHumansMyelin-Oligodendrocyte GlycoproteinVaccinationAutoantibodiesBNT162 VaccineCOVID-19 VaccinesMyelin-Oligodendrocyte Glycoproteinanti-MOG antibody-associated diseaseMOGSARS-CoV-2steroidvaccination

Identifiers

PMID36575011
PMCPMC10076135
OpenAlexW4313237450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.